Deadline: May 28, 2013 for Letter of Intent; June 18, 2013 for Full Proposal
This Funding Opportunity Announcement provides funds from the Disaster Relief Appropriations Act of 2013 (P.L. 113-02) to address two priority areas to aid recovery from the public health impact of Hurricane Sandy, 1) conduct training in mold mitigation and health-related research, and 2) conduct assessments of health hazards and outcomes among response and recovery workers and volunteers responding to Super-storm Sandy. This research program is within the HHS and CDC overall strategy to build the scientific evidence-base and its application to public health preparedness, response, and recovery practice. Funds will be provided to benefit all or part of the Federal Emergency Management Agency (FEMA) declared major disaster states, which are: Connecticut, Delaware, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, Rhode Island, West Virginia, Virginia, and the District of Columbia.
Deadlines: Pre-application submission June 19, 2013; Invitation to submit an application August 2, 2013; Application for submission deadline: October 9, 2013
The Transformative Impact Award supports prostate cancer research with near-term clinical relevance that will transform and revolutionize the clinical management of prostate cancer and make a major contribution to the elimination of death from prostate cancer and enhancing the well-being of men experiencing the impact of the disease.
For the purpose of this award, clinical management of prostate cancer includes the wide spectrum of screening, detection, diagnosis, prognosis, and/or treatment.
Deadlines: Pre-application Deadline June 19, 2013; Invitation to Submit August 2, 2013; Application Submission deadling October 9, 2013
The PCRP Laboratory – Clinical Transition Award (LCTA) mechanism was introduced in FY07. Since then, 95 applications have been received, and 12 have been recommended for funding. The LCTA supports product-driven preclinical studies of promising lead agents or medical devices that have the potential to revolutionize prostate cancer clinical care.
Deadlines: Pre-application June 19, 2013; Invitation to Submit August 2, 2013; Application Submission Deadline: October 9, 2013
The PCRP Biomarker Development Award was introduced in FY12 to fund near-term validation or qualification studies that will advance known prostate cancer biomarkers into the clinical setting. Specifically, this award will support high-impact research aimed at multi-institutional validation and/or qualification of prostate cancer biomarkers for crucial decision-making in prostate cancer management, including detection of aggressive disease, prognosis and progression, and prediction and assessment of response to therapy.
It is anticipated that studies supported through this award will produce clinically useful biomarkers that will provide improved specificity for detection of clinically relevant prostate cancer, as well as distinguish between aggressive and indolent disease, which will in turn reduce the burdens of prostate cancer overtreatment and improve the clinical management of this disease. Proposed projects should demonstrate a high potential for commercialization and clinical use of the projects’ outcomes. As such, the inclusion of clinical trials is allowed.
Deadlines: Pre-application deadline: July 2; Invitation to Submit August 2013; Application Deadline: October 8, 2013
The ARP Pilot Award supports conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ASD forward. Research projects should include a testable hypothesis based on a strong scientific rationale. This award is not intended to support the continuation of existing studies or the next logical extension and/or incremental step.
The Pilot Award is designed to support innovative ideas with the potential to yield impactful data and new avenues of investigation. The existence of preliminary data suggests that the proposed research does not meet the intent of this award mechanism. Therefore, preliminary data are not allowed. The strength of the application should be based on sound scientific rationale and logical reasoning.
Deadline: Pre-application June 19, 2013; Invitation to Submit August 2, 2013; Application Submission Deadline October 9, 2013
These investigators should use complementary and synergistic perspectives to address a central problem or question in prostate cancer research. This award is designed to support both new and pre-existing partnerships. The overall goal of this award is to significantly accelerate advances in prostate cancer research to support the PCRP vision of conquering prostate cancer. Although groundbreaking research often involves a degree of risk, applications should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature.
Due to this award’s emphasis on innovation, presentation of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required.
Deadline: Pre-application Deadline June 19, 2013; Invitation to Submit August 8, 2013; Application Submission Deadline October 2, 2013
The Idea Development Award supports new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission. Although groundbreaking research often involves a degree of risk, applications should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature.
Due to this award’s emphasis on innovation, the presentation of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Research deemed innovative may represent a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other highly creative qualities. Research that is an incremental advance
upon published data is not considered innovative.
Deadline: Pre-application Deadline June 12; Invitation to Submit July 2013; September 18, 2013 for Full Proposal
The FY13 GWIRP is offering two award mechanisms to evaluate potential interventions for Gulf War Illness: the Innovative Treatment Evaluation Award (ITEA) and the Clinical Trial Award (CTA).
Deadline: June 10, 2013 for White Paper
This CALL is directed toward increasing knowledge and understanding of corrosion mode or prototype systems rather than focusing on a specific system or hardware solution. Potential recipient’s research and development efforts will help expedite technology transition from laboratory to operational use and may involve risk reduction initiatives. Specific research and development outcomes should lead to materials, processes, and methodologies that can be used to prevent and control corrosion of materials and structures of systems and facilities, with the ultimate goal of reducing costs, improving availability of systems, and increasing the safety of military, government, and industry assets.
Projects must be new research efforts. Proposals for the continuation of existing research projects funded under previous grant or cooperative agreement awards are not desired. Collaboration among proposing institutions is strongly encouraged.
Deadline: June 18, 2013 for Pre-Application Deadline; July 2 for Confidential Letters of Recommendation; July 2, 2013 Deadline for Full Proposal
The Era of Hope Scholar Award supports individuals who are early in their careers and have demonstrated significant potential for innovation in breast cancer research. These individuals should be exceptionally talented scientists who have shown that they are the “best and brightest” in their field(s) through extraordinary creativity, vision, and productivity. They should have demonstrated experience in forming effective partnerships and collaborations and should exhibit strong potential for leadership in the breast cancer research community. Since the intent of the Era of Hope Scholar Award is to recognize creative and innovative individuals rather than projects, the central feature of the award is the innovative contribution that the Principal Investigator (PI) can make toward ending breast cancer. The PI should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.
Experience in breast cancer research is not required; however, the application must focus on breast cancer and the PI must commit at least 50% of his/her full-time professional effort during the award period to breast cancer research.